PET Imaging of GABA Receptors in Succinic Semialdehyde Dehydrogenase Deficiency
NCT00246870 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 42
Last updated 2017-07-02
Summary
This study will use brain imaging to map brain cell receptors for a chemical called GABA, a chemical that inhibits the activities of nerve cells. The study includes patients with succinic semialdehyde dehydrogenase deficiency, or SSADH (a disorder in which an enzyme deficiency disrupts GABA metabolism), their parents, and healthy volunteers. SSADH deficiency causes various neurological and neuromuscular problems, including mild to severe mental retardation, delays in the acquisition of skills requiring the coordination of mental and physical activities (psychomotor retardation), delays in language and speech development, and other symptoms.
Healthy volunteers 18-55 years of age, patients with SSADH between 5 and 24 years of age, and parents of patients 18-55 years of age may be eligible for this study.
Participants undergo magnetic resonance imaging (MRI) and positron emission tomography (PET) scanning as follows:
Magnetic resonance imaging
MRI uses a magnetic field and radio waves to produce images of body tissues and organs. For this procedure, the subject lies on a table that is moved into the scanner (a narrow metal cylinder surrounded by a magnetic field) wearing earplugs to muffle loud knocking and thumping sounds that occur during the scanning process. Scanning time varies from 20 minutes to 3 hours, with most scans lasting between 45 and 90 minutes. Participants may be asked to lie still for up to 90 minutes at a time. In addition to standard MRI, participants may also have new types of MRI that may detect brain abnormalities when regular MRI is normal, such as diffusion tensor MRI and magnetic resonance spectroscopy. There are no noticeable differences from ordinary MRI scans.
Positron Emission Tomography
A catheter (plastic tube) is placed in a vein in the subject's wrist. The subject lies on a table with his or her head placed in the scanner. A mask, used to help keep the head still in the scanner, is placed over the head. The mask is not uncomfortable and has holes for the subject to see through. A radioactive compound called flumazenil is injected into a vein. The scan takes about 90 minutes.
Some children need to be sedated for PET or MRI scans. In these cases, chloral hydrate, a standard drug for pediatric diagnostic procedures, is used.
...
Conditions
- Succinic Semialdehyde Dehydrogenase Deficiency
- SSADH Deficiency
Sponsors & Collaborators
-
National Institute of Neurological Disorders and Stroke (NINDS)
lead NIH
Eligibility
- Min Age
- 5 Years
- Max Age
- 55 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2005-10-24
- Completion
- 2010-10-19
Countries
- United States
Study Locations
More Related Trials
-
Imaging Blood Brain Imaging Dysfunction in Parkinson's Disease
NCT02605161 ·Status: COMPLETED
-
PET Whole Body Biodistribution and Test Retest Bain Imaging Studies Using a Phosphodiesterase 4 Inhibitor (R)-[11C]Rolipram
NCT00250172 ·Status: COMPLETED ·Phase: PHASE1
-
Brain Blood Flow Studies of Language and Memory
NCT00001288 ·Status: COMPLETED
-
Metabolic Abnormalities in Children With Epilepsy
NCT00001325 ·Status: COMPLETED
-
A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of [18F]NAV4694 PET for Detection of Cerebral Beta-Amyloid When Compared With Postmortem Histopathology
NCT01886820 ·Status: UNKNOWN ·Phase: PHASE3
-
Neurologic Deficits and Recovery in Chronic Subdural Hematoma
NCT05900557 ·Status: WITHDRAWN ·Phase: NA
-
PET Scan to Map the Areas of the Brain Involved in Planning
NCT00001363 ·Status: COMPLETED
-
The Synapse Project
NCT04871074 ·Status: COMPLETED ·Phase: PHASE2
-
Supplementing Neuro-Energy to Aid Cognition
NCT06767124 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Positron Emission Tomography (PET) to Study Brain Signaling
NCT00044200 ·Status: COMPLETED
-
PET Scans in Normal Volunteers and Patients With Fabry Disease
NCT00005111 ·Status: COMPLETED
-
fMRI in Blood Phobia Syncope
NCT00715065 ·Status: WITHDRAWN
-
Safety and Efficacy of Positron Emission Tomography Imaging With MNI-513
NCT01000870 ·Status: TERMINATED ·Phase: EARLY_PHASE1
-
Assess Fibrin in Brains With AD/ADRD
NCT05336695 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Evaluation of [18F]APN-1607 PET Uptake in Alzheimer's Disease Patients Compared With Healthy Subjects
NCT04141150 ·Status: UNKNOWN ·Phase: PHASE2
-
Magnetic Resonance Imaging to Investigate Silent Strokes During Neck and Skull Angioplasty
NCT00015717 ·Status: COMPLETED
-
Clinico-Pathologic-Genetic-Imaging Study of Neurodegenerative and Related Disorders
NCT04680130 ·Status: ENROLLING_BY_INVITATION
-
Efficacy and Safety of the PET Imaging Agent [18F]NAV4694 in Subjects With Probable Alzheimer's Disease
NCT01680588 ·Status: UNKNOWN ·Phase: PHASE2
-
Evaluation of [18F] FMH3 and PET as a Marker of Histamine-3 Receptor Activity in Subjects With AD Compared w/ HC
NCT01268020 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
PET Scan in Patients With Neurocardiologic Disorders
NCT00001418 ·Status: COMPLETED
-
4-Repeat Tauopathy Neuroimaging Initiative - Cycle 2
NCT02966145 ·Status: COMPLETED
-
Magnetic Resonance Imaging (MRI) of Brain Iron in Neurodegenerative Disease
NCT00249080 ·Status: COMPLETED
-
Utilization of 31P-Nuclear Magnetic Resonance Spectroscopy to Monitor Brain Energy Deficit in Huntington Disease
NCT01696708 ·Status: COMPLETED ·Phase: NA
-
Imaging Glutamate Release From Alcohol
NCT04159688 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Hyperintense: Midlife Hypertension and the Brain
NCT06175663 ·Status: RECRUITING